Sarepta (SRPT) Pops Higher as Glaxo's DMD Drug Drisapersen Falters
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Outlook Therapeutics (OTLK) halted, news pending
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
Sarepta (SRPT) May Seek Partner in Europe as Eteplirsen Tests Continue
January 11, 2013 9:21 AM ESTSarepta Therapeutics (Nasdaq: SRPT) is ticking higher amid chatter that it might seek to form an overseas partnership for its Duchenne muscular dystrophy (DMD)... More
